

M.K. DANDEKER & CO LLP
Chartered Accountants

Phone : +91-44-43514233
E-mail : admin@mkdandeker.com
Web : www.mkdandeker.com

No.185 (Old No.100) 2nd Floor,
Poonamallee High Road,
Kilpauk, CHENNAI - 600 010.

**CERTIFICATE ON
WEIGHTED AVERAGE PRICE AND COST OF ACQUISITION OF SHARES**

Date: January 23, 2025

To,

The Board of Directors,
Dr. Agarwal's Health Care Limited
1st Floor, Buhari Towers,
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School,
Chennai - 600006,
Tamil Nadu, India


Kotak Mahindra Capital Company Limited
27BKC, 1st Floor, Plot No. C – 27
"G" Block, Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051

Jefferies India Private Limited
Level 16, Express Towers,
Nariman Point,
Mumbai - 400021
Maharashtra, India

Morgan Stanley India Company Private Limited
Altimus, Level 39 & 40,
Pandurang Budhkar Marg, Worli
Mumbai 400013
Maharashtra, India

Motilal Oswal Investment Advisors Limited
Motilal Oswal Tower
Rahimtullah Sayani Road
Opposite Parel ST Depot
Prabhadevi, Mumbai - 400 025
Maharashtra, India

(Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Private Limited and Motilal Oswal Investment Advisors Limited are collectively referred to as the "Book Running Lead Managers" or the "BRLMs")



Branches : AHMEDABAD, BENGALURU, CHENNAI, HYDERABAD
M.K. Dandeker & Co., a partnership firm converted into M.K. Dandeker & Co LLP
(A Limited Liability Partnership with LLP Identification No:ACA-6550) with effect from 19-04-2023

Re: Proposed initial public offering of equity shares of face value of ₹ 1 each ("Equity Shares") by Dr. Agarwal's Health Care Limited (the "Company") and such offering (the "Offer")

We, **M.K. Dandeker & Co. LLP**, independent chartered accountants engaged by the Company for the purpose of the Offer, have performed the procedures stated below as requested by the Company in relation to the accompanied statement of the cost per share to the promoter(s) and selling shareholders in the Offer, (the "**Statement**") as on the date of this certificate, prepared by the management of the Company.

We have performed the following procedures:

- (i) Obtained the list of promoter(s) and promoter group as defined under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**") (such persons "**Promoters**" and "**Promoter Group**" respectively), details of the selling shareholders who have agreed to participate in the Offer (the "**Selling Shareholders**") and list of other shareholders holding the right to nominate director(s) on the board of the Company ("**Other Shareholders**"), from the management of the Company for the purpose of calculation of cost per Equity Shares of the respective person;
- (ii) Compared the date of acquisition / sale / transfer; number of Equity Shares; and acquisition / issue cost per equity share in respect of the Promoters, and members of the Promoter Group (where applicable), Selling Shareholders and Other Shareholders, including shareholders with special rights stated in the Statement, with the share allotment register, minutes of the meetings of the board of directors of the Company and duly organized committees thereof, minutes of annual general meeting and extra ordinary general meetings, relevant statutory registers, relevant forms including share transfer forms, demat statements, depository instruction slips and other documents as may be deemed relevant;
- (iii) Computed the average cost per Equity Shares to the Promoters and Selling Shareholder as on the date of this certificate;
- (iv) Computed the weighted average price at which the Equity Shares were acquired by the Promoters and Selling Shareholders in the last three (3) years, eighteen (18) months and one (1) year, from the date of this certificate;
- (v) Computed the weighted average cost of acquisition of Equity Shares by the Promoters and the Selling Shareholders since the date of first subscription to MoA;
- (vi) Computed weighted average cost of acquisition of all shares transacted in last three (3) years, eighteen (18) months and one (1) year, from the date of this certificate;
- (vii) Computed weighted average cost of acquisition per Equity Shares based on the new issue of shares (equity or convertible securities) during the eighteen (18) months prior to the date of this certificate (excluding shares issued under ESOP / ESOS and bonus shares) where such issuance was equal to or more than 5% of fully diluted paid up share capital of the Company and computed the weighted average price of all such primary issuance; and



- (viii) Computed weighted average cost of acquisition per Equity Shares based on secondary sale or acquisition of shares (equity or convertible securities) by Promoters, Promoter Group, the Selling Shareholders and / or the Other Shareholders during eighteen (18) months prior to the date of this certificate (excluding gifts) and where such sale or acquisition was equal to or more than 5% of fully diluted paid up share capital of the Company and computed the weighted average price of all such secondary issuance.

For (vii) and (viii) above,

- (a) we have considered each transaction during the above-mentioned period individually as well as multiple transactions combined together over a span of rolling 30 days;
- (b) we have calculated the size of the issuance, sale or acquisition, as the case may be, based on pre-issue capital before such transaction on a fully diluted basis (excluding employee stock options granted but not vested);
- (c) the price per Equity Shares has been adjusted for the corporate actions (such as split or bonus) done by the Company;
- (ix) reviewed the relevant shareholders agreements including amendments agreements / waiver letters, as applicable, thereto for identifying the shareholders of the Company who are entitled with the right to nominate directors or any other rights post listing; and
- (x) reviewed the relevant financial statements, relevant minutes of the meetings of the board of directors of the Company (the "Board"), forms filed with the RoC, Form 2 / PAS-3, transfer deeds, transfer registers, FCGPR and other documents presented to us and explanations provided to us by the Company.

Based on above procedures, we confirm that:

- (i) The weighted average price at which Equity Shares of the Company in the last one (1) year i.e. from January 23, 2024 till January 23, 2025 were acquired by the Promoters and Selling Shareholders, as on the date of this Certificate, is as set out in **Annexure A**.
- (ii) The weighted average price at which Equity Shares of the Company in the last three (3) years i.e. from January 23, 2022 till January 23, 2025 were acquired by the Promoters and Selling Shareholders, as on as on the date of this Certificate, is as set out in **Annexure B**.
- (iii) The weighted average price at which Equity Shares of the Company in the last eighteen (18) months i.e. from July 23, 2023 till January 23, 2025 were acquired by the Promoters and Selling Shareholders, as on as on the date of this Certificate, is as set out in **Annexure C**.
- (iv) The average cost of acquisition of Equity Shares by the Promoters and Selling Shareholders and the computation of the average cost of acquisition of the Equity Shares is as set out in **Annexure D**.
- (v) The weighted average cost of acquisition of Equity Shares by the Promoters and the Selling Shareholders since the date of first subscription to MoA is as set out in **Annexure E**.



- (vi) The weighted average cost of acquisition of all shares transacted in last three (3) years, eighteen (18) months and one (1) year, from the date of this certificate is as set out in **Annexure F**.
- (vii) The weighted average cost of acquisition per Equity Share based on the new issue of shares (equity or convertible securities) during eighteen (18) months prior to the date of this certificate (excluding shares issued under ESOP / ESOS and bonus shares) where such issuance was equal to or more than 5% of fully diluted paid up share capital of the Company is set out in **Annexure G**, along with computation of the weighted average price of all such primary issuance.
- (viii) The weighted average cost of acquisition per Equity Shares based on secondary sale or acquisition of shares (equity or convertible securities) by Promoters, Promoter Group, the Selling Shareholders and / or the Other Shareholders during eighteen (18) months prior to the date of this certificate (excluding gifts) and where such sale or acquisition was equal to or more than 5% of fully diluted paid up share capital of the Company is set out in **Annexure H**, along with the computation of weighted average price of all such secondary issuance.
- (ix) The weighted average cost of acquisition of all shares based on primary / secondary transaction(s) pursuant to (vii) and (viii) mentioned above is set out in **Annexure I**.

We have conducted our examination in accordance with the "Guidance Note on Reports or Certificates for Special Purposes (Revised 2016)" ("**Guidance Note**") issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India. We have also complied with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial information, and Other Assurance and Related Services Engagements.

This certificate is issued for the sole purpose of the Offer, and can be used, in full or part, for inclusion in the red herring prospectus, prospectus and any other material used in connection with the Offer (together, the "**Offer Documents**"), and for the submission of this certificate as may be necessary, to any regulatory / statutory authority, stock exchanges, any other authority as may be required and/or for the records to be maintained by the Book Running Lead Managers in connection with the Offer and in accordance with applicable law, and for the purpose of any defence the Book Running Lead Managers may wish to advance in any claim or proceeding in connection with the contents of the Offer Documents.

This certificate may be relied on by the Company, the BRLMs, their affiliates and legal counsel in relation to the Offer.

We undertake to update you in writing of any changes in the abovementioned position informed to us by the management of the Company in writing, until the date the Equity Shares issued pursuant to the Issue commence trading on the stock exchanges. In the absence of any communication from us till the Equity Shares commence trading on the stock exchanges, you may assume that there is no change in respect of the matters covered in this certificate.



All capitalized terms used but not defined herein shall have the meaning assigned to them in the Offer Documents.

Yours faithfully,

For and on behalf of M.K. Dandeker & Co. LLP,
Chartered Accountants
Firm Regn. No.: 000679S/S000103



Name: S. Poosaidurai
Designation: Partner
Membership Number: 223754
Date: January 23, 2025
Place: Chennai
UDIN: 25223754BMHWTT4885

Cc:

Domestic Legal Counsel to the BRLMs

S&R Associates

One World Center
1403 Tower 2 B
841, Senapati Bapat Marg, Lower Parel
Mumbai - 400013
Maharashtra, India

International Legal Counsel to the BRLMs

Sidley Austin LLP

Level 31
Six Battery Road
Singapore 049909

Domestic Legal Counsel to the Company

Cyril Amarchand Mangaldas

3rd Floor
Prestige Falcon Towers 19
Brunton Road
Bengaluru 560 025
Karnataka, India



ANNEXURE A

Summary of Weighted Average Price of Equity Shares acquired in last one (1) year from the date of this Certificate by the Promoters and Selling Shareholders

Name of the Promoters and Selling Shareholders	No. of Equity Shares held as of January 23, 2025	% of Pre-Offer paid-up share capital on fully diluted basis	No. of Equity Shares acquired in the last one (1) year	Weighted average price of Equity Shares acquired in the last one (1) year (In ₹)
Promoters and Promoter Group				
Dr. Amar Agarwal	1,78,24,560	5.78	1,35,91,070	51.76
Dr. Athiya Agarwal	2,15,59,680	6.99	1,84,39,070	51.76
Dr. Adil Agarwal	1,76,30,640	5.71	1,34,43,210	51.76
Dr. Anosh Agarwal	2,20,73,430	7.16	1,68,30,800	51.76
Dr. Ashwin Agarwal	1,52,85,390	4.95	1,01,90,280	-
Dr. Ashar Agarwal	4,93,020	0.16	3,28,680	-
Dr. Agarwal's Eye Institute - Partnership Firm	1,54,24,230	5.00	1,17,60,840	51.76
Dr. Agarwal's Eye Institute Private Limited	43,42,320	1.41	28,94,880	-
Dr. Adil Agarwal Family Trust	30	Negligible	30	-
Dr. Anosh Agarwal Family Trust	30	Negligible	30	-
Dr. Ashwin Agarwal Family Trust	30	Negligible	30	-
Dr. Ashar Agarwal Family Trust	30	Negligible	30	-
Dr. Amar Agarwal Family Trust	30	Negligible	30	-
M/s. Farah Agarwal	8,63,130	0.28	6,88,130	51.76
M/s. Urmila Agarwal	8,63,100	0.28	6,88,110	51.77
Selling Shareholders				
Arvon Investments Pte. Ltd	3,83,58,480	12.44	2,55,72,320	-
Claymore Investments (Mauritius) Pte. Ltd	4,84,44,450	15.71	3,22,86,300	-
Hyperton Investments Pte. Ltd.	10,39,49,580	33.70	6,92,99,720	-



ANNEXURE A

Computation of Weighted Average Price of Equity Shares acquired in last one (1) year from the date of this Certificate by the Promoters and Selling Shareholders

Nature of Transaction (Each Promoters and Selling Shareholders wise)	Nature of Consideration (Cash / Other than Cash)	Date of Acquisition	No. of Equity shares	Face value of the Equity Shares (in ₹)	Acquisition per Equity Share (including securities premium) (in ₹)	Total Acquisition Cost (in ₹)	Cumulative Amount paid for the Equity Shares (in ₹)	Cumulative No. of Equity Shares
Dr. Amar Agarwal								
Allocation of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,934	10	4,118.94	23,45,07,729.96	23,45,07,729.96	56,934
Allocation of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,10,859	10	4,118.94	46,90,19,978.66	70,35,27,308.62	1,70,803
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,35,27,308.62	1,70,803
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,35,27,308.62	1,35,91,070.00
					51.76			
Dr. Athiya Agarwal								
Allocation of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	68,885	10	4,118.94	28,36,50,803.10	28,36,50,803.10	68,885
Allocation of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,37,730	10	4,118.94	56,73,01,503.20	85,09,52,409.30	2,06,595
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,09,52,409.30	2,06,595
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,09,52,409.30	1,64,39,070
					51.76			
Dr. Aditi Agarwal								
Allocation of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,315	10	4,118.94	23,19,95,106.10	23,19,95,106.10	56,315
Allocation of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,12,630	10	4,118.94	46,35,16,212.20	69,56,74,318	1,69,945
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,17,53,780	1	-	-	69,56,74,318	1,69,945
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,17,53,780	1	-	-	69,56,74,318	1,34,43,210
					51.76			
Dr. Anosh Agarwal								
Allocation of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	70,506	10	4,118.94	29,04,09,893.64	29,04,09,893.64	70,506
Allocation of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,41,012	10	4,118.94	58,06,19,967.28	87,12,29,859.92	2,11,518
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	87,12,29,859.92	2,11,518
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	87,12,29,859.92	1,68,30,800
					51.76			
Dr. Ashwin Agarwal								
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,01,90,280	1	-	-	-	1,01,90,280
Dr. Ashar Agarwal								
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	3,28,680
Dr. Agarwal's Eye Institute - Partnership Firm								
Allocation of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	49,267	10	4,118.94	20,39,27,616.98	20,39,27,616.98	49,267
Allocation of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	96,335	10	4,118.94	40,59,33,332.90	60,97,67,666.88	1,47,802
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,02,82,820	1	-	-	60,97,67,666.88	1,47,802
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	1,02,82,820	1	-	-	60,97,67,666.88	1,17,60,840
					51.76			
Dr. Agarwal's Eye Institute Private Limited								
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Share	Other than Cash	September 09, 2024	28,94,880	1	-	-	-	28,94,880



		Weighted average cost per Equity Share (in ₹)					
Ms. Farah Aqarwal							
Alignment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	2,757
Alignment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	3,40,67,752.74	8,271
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	5,75,400	1	-	2,27,11,835.16	82,710
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	5,75,400	1	-	3,40,67,752.74	6,58,130
					51.76		
Weighted average cost per Equity Share (in ₹)							
Ms. Umilia Aqarwal							
Alignment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	2,757
Alignment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	3,40,67,752.74	8,271
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	5,75,400	1	-	2,27,11,835.16	82,710
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	5,75,400	1	-	3,40,67,752.74	6,58,110
					51.77		
Weighted average cost per Equity Share (in ₹)							
Dr. Adil Aqarwal Family Trust							
Gift Received	Other than cash	August 19, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (in ₹)							
Dr. Anosh Aqarwal Family Trust							
Gift Received	Other than cash	August 20, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (in ₹)							
Dr. Ashim Aqarwal Family Trust							
Gift Received	Other than cash	August 19, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (in ₹)							
Dr. Ashar Aqarwal Family Trust							
Gift Received	Other than cash	August 19, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (in ₹)							
Dr. Amar Aqarwal Family Trust							
Gift Received	Other than cash	August 28, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (in ₹)							
Anvon Investments Pte. Ltd							
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	2,55,72,320	1	-	-	2,55,72,320
Weighted average cost per Equity Share (in ₹)							
Claymore Investments (Maharashtra) Pte. Ltd							
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	3,22,95,300	1	-	-	3,22,95,300
Weighted average cost per Equity Share (in ₹)							
Hydrexion Investments Pte. Ltd.							
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	6,92,99,720	1	-	-	6,92,99,720
Weighted average cost per Equity Share (in ₹)							



ANNEXURE B

Summary of Weighted Average Price of Equity Shares acquired in the last three (3) years from the date of this Certificate by the Promoters and Selling Shareholders

Name of the Promoters and Selling Shareholders	No. of Equity Shares held as of January 23, 2025	% of Pre-Offer paid-up share capital on fully diluted basis	No. of Equity Shares acquired in the last three (3) years	Weighted average price of Equity Shares acquired in the last three (3) years (In ₹)
Promoters and Promoter Group				
Dr. Amar Agarwal	1,78,24,560	5.78	1,35,91,070	51.76
Dr. Athiya Agarwal	2,15,59,680	6.99	1,64,39,070	51.76
Dr. Adil Agarwal	1,76,30,640	5.71	1,34,43,210	51.76
Dr. Anosh Agarwal	2,20,73,430	7.16	1,68,30,800	51.76
Dr. Ashvin Agarwal	1,52,85,390	4.95	1,01,90,260	-
Dr. Ashar Agarwal	4,93,020	0.16	3,28,680	-
Dr. Agarwal's Eye Institute - Partnership Firm	1,54,24,230	5.00	1,17,60,840	51.76
Dr. Agarwal's Eye Institute Private Limited	43,42,320	1.41	28,94,880	-
Dr. Adil Agarwal Family Trust	30	Negligible	30	-
Dr. Anosh Agarwal Family Trust	30	Negligible	30	-
Dr. Ashvin Agarwal Family Trust	30	Negligible	30	-
Dr. Ashar Agarwal Family Trust	30	Negligible	30	-
Dr. Amar Agarwal Family Trust	30	Negligible	30	-
Ms. Farah Agarwal	8,63,130	0.28	6,58,130	51.76
Ms. Urmila Agarwal	8,63,100	0.28	6,58,110	51.77
Selling Shareholders				
Arvon Investments Pte. Ltd	3,83,58,480	12.44	3,83,58,480	125.20
Claymore Investments (Mauritius) Pte. Ltd	4,84,44,450	15.71	3,22,96,300	-
Hyperion Investments Pte. Ltd.	10,39,49,580	33.70	10,39,49,580	117.88



ANNEXURE B

Computation of Weighted Average Price of Equity Shares acquired in the last three (3) years from the date of this Certificate by the Promoters and Selling Shareholders

Nature of Transaction (Each Promoters and Selling Shareholders wise)	Nature of Consideration (Cash / other than Cash)	Date of Acquisition	No. of Equity shares	Face value of the Equity Shares (in ₹)	Acquisition per Equity Share (including securities premium) (in ₹)	Total Acquisition Cost (in ₹)	Cumulative Amount paid for the Equity Shares (in ₹)	Cumulative No. of Equity Shares
Dr. Amar Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,934	10	4,118.94	23,45,07,729.96	23,45,07,729.96	56,934
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,13,889	10	4,118.94	46,90,19,578.86	70,35,27,308.82	1,70,803
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.							70,35,27,308.82	17,08,030
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,35,27,308.82	1,35,91,070.00
					51.76			
					Weighted average cost per Equity Share (in ₹)			
Dr. Athiya Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	68,865	10	4,118.94	28,36,50,803.10	28,36,50,803.10	68,865
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,37,730	10	4,118.94	56,73,01,606.20	85,09,52,409.30	2,06,595
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.							85,09,52,409.30	20,65,950
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,09,52,409.30	1,64,39,070
					51.76			
					Weighted average cost per Equity Share (in ₹)			
Dr. Adil Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,315	10	4,118.94	23,19,58,106.10	23,19,58,106	56,315
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,12,630	10	4,118.94	46,39,16,212.20	69,58,74,318	1,68,945
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.							69,58,74,318	16,89,450
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,17,53,760	1	-	-	69,58,74,318	1,34,43,210
					51.76			
					Weighted average cost per Equity Share (in ₹)			
Dr. Anosh Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	70,506	10	4,118.94	29,04,09,983.64	29,04,09,983.64	70,506
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,41,012	10	4,118.94	58,08,19,867.28	87,12,29,950.92	2,11,518
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.							87,12,29,950.92	21,15,180
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	87,12,29,950.92	1,68,30,800
					51.76			
					Weighted average cost per Equity Share (in ₹)			
Dr. Ashvin Agarwal								
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,01,90,260	1	-	-	-	1,01,90,260
					Weighted average cost per Equity Share (in ₹)			
Dr. Ashar Agarwal								
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	3,28,680
					Weighted average cost per Equity Share (in ₹)			
Dr. Agarwal's Eye Institute - Partnership Firm								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	49,267	10	4,118.94	20,29,27,816.98	20,29,27,816.98	49,267
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	98,535	10	4,118.94	40,58,59,752.90	60,87,87,569.88	1,47,802
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.							60,87,87,569.88	14,78,020
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,02,82,820	1	-	-	60,87,87,569.88	1,17,60,840
					51.76			
					Weighted average cost per Equity Share (in ₹)			
Dr. Agarwal's Eye Institute Private Limited								
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	28,94,880	1	-	-	-	28,94,880



Ms. Farah Agarwal										
Weighted average cost per Equity Share (in ₹)										
Alotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	2,757	2,757	
Alotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	3,40,67,752.74	8,271	8,271	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	5,75,420	1	-	-	3,40,67,752.74	82,710	82,710	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	5,75,420	1	-	-	3,40,67,752.74	6,58,130	6,58,130	
Weighted average cost per Equity Share (in ₹)										
Ms. Urmila Agarwal										
Weighted average cost per Equity Share (in ₹)										
Alotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	2,757	2,757	
Alotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	3,40,67,752.74	8,271	8,271	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	5,75,400	1	-	-	3,40,67,752.74	82,710	82,710	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	5,75,400	1	-	-	3,40,67,752.74	6,58,110	6,58,110	
Weighted average cost per Equity Share (in ₹)										
Dr. Adil Agarwal Family Trust										
Weighted average cost per Equity Share (in ₹)										
Gift Received	Other than cash	August 19, 2024	1	10	-	-	-	-	1	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	-	10	10	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	20	1	-	-	-	30	30	
Weighted average cost per Equity Share (in ₹)										
Dr. Anosh Agarwal Family Trust										
Weighted average cost per Equity Share (in ₹)										
Gift Received	Other than cash	August 20, 2024	1	10	-	-	-	-	1	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	-	10	10	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	20	1	-	-	-	30	30	
Weighted average cost per Equity Share (in ₹)										
Dr. Ashvin Agarwal Family Trust										
Weighted average cost per Equity Share (in ₹)										
Gift Received	Other than cash	August 19, 2024	1	10	-	-	-	-	1	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	-	10	10	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	20	1	-	-	-	30	30	
Weighted average cost per Equity Share (in ₹)										
Dr. Ashar Agarwal Family Trust										
Weighted average cost per Equity Share (in ₹)										
Gift Received	Other than cash	August 20, 2024	1	10	-	-	-	-	1	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	-	10	10	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	20	1	-	-	-	30	30	
Weighted average cost per Equity Share (in ₹)										
Arvon Investments Pte. Ltd										
Weighted average cost per Equity Share (in ₹)										
Alotment of Equity Shares pursuant to conversion of Series C-CCPS	Cash	April 28, 2022	53,024	10	3,185.67	16,89,16,966.08	16,89,16,966.08	53,024	53,024	
Private placement	Cash	May 05, 2022	5,95,420	10	3,185.67	1,89,99,37,301.40	2,06,89,14,267.48	6,49,444	6,49,444	
Transfer - Purchase	Cash	May 05, 2022	11,524	10	3,185.74	3,67,12,500.00	2,10,56,26,767.48	6,60,968	6,60,968	
Transfer - Purchase	Cash	May 05, 2022	93,242	10	3,185.66	29,70,37,500.00	2,40,26,64,267.48	7,54,210	7,54,210	
Rights issue	Cash	August 10, 2023	5,24,406	10	4,576.60	2,39,99,96,499.60	4,80,26,60,767.08	12,78,616	12,78,616	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	2,55,72,320	1	-	-	4,80,26,60,767.08	1,27,86,160	1,27,86,160	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	2,55,72,320	1	-	-	4,80,26,60,767.08	3,33,58,480	3,33,58,480	
Weighted average cost per Equity Share (in ₹)										
Claymore Investments (Mauritius) Pte. Ltd										
Weighted average cost per Equity Share (in ₹)										
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	3,22,95,300	1	-	-	-	3,22,95,300	3,22,95,300	
Weighted average cost per Equity Share (in ₹)										
Hyperion Investments Pte. Ltd.										
Weighted average cost per Equity Share (in ₹)										
Private placement	Cash	May 05, 2022	3,45,296	10	3,185.67	1,09,99,99,108.32	1,09,99,99,108.32	3,45,296	3,45,296	
Transfer - Purchase	Cash	May 05, 2022	22,45,679	10	3,185.68	7,15,40,07,610.00	8,25,40,06,718.32	25,90,975	25,90,975	
Rights issue	Cash	August 10, 2023	8,74,011	10	4,576.60	4,00,00,00,000.00	12,25,40,06,718.32	34,64,986	34,64,986	
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	6,92,89,720	1	-	-	12,25,40,06,718.32	3,46,49,860	3,46,49,860	
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Share	Other than Cash	September 09, 2024	6,92,89,720	1	-	-	12,25,40,06,718.32	10,39,49,580	10,39,49,580	
Weighted average cost per Equity Share (in ₹)										
117.88										



ANNEXURE C

Summary of Weighted Average Price of Equity Shares acquired in the last eighteen (18) months from the date of this Certificate by the Promoters and Selling Shareholders

Name of the Promoters and Selling Shareholders	No. of Equity Shares held as of January 23, 2025	% of Pre-Offer paid-up share capital on fully diluted basis	No. of Equity Shares acquired in the last eighteen (18) months	Weighted average price of Equity Shares acquired in the last eighteen (18) months (in ₹)
Promoters and Promoter Group				
Dr. Amar Agarwal	1,78,24,560	5.78	1,35,91,070	51.76
Dr. Athiya Agarwal	2,15,59,680	6.99	1,64,39,070	51.76
Dr. Adil Agarwal	1,76,30,640	5.71	1,34,43,210	51.76
Dr. Anosh Agarwal	2,20,73,430	7.16	1,68,30,800	51.76
Dr. Ashvin Agarwal	1,52,85,390	4.95	1,01,90,260	-
Dr. Ashar Agarwal	4,93,020	0.16	3,28,680	-
Dr. Agarwal's Eye Institute - Partnership Firm	1,54,24,230	5.00	1,17,60,840	51.76
Dr. Agarwal's Eye Institute Private Limited	43,42,320	1.41	28,94,880	-
Dr. Adil Agarwal Family Trust	30	Negligible	30	-
Dr. Anosh Agarwal Family Trust	30	Negligible	30	-
Dr. Ashvin Agarwal Family Trust	30	Negligible	30	-
Dr. Ashar Agarwal Family Trust	30	Negligible	30	-
Dr. Amar Agarwal Family Trust	30	Negligible	30	-
Ms. Farah Agarwal	8,63,130	0.28	6,58,130	51.76
Ms. Urmila Agarwal	8,63,100	0.28	6,58,110	51.77
Selling Shareholders				
Arvon Investments Pte. Ltd	3,83,58,480	12.44	3,08,16,380	77.88
Claymore Investments (Mauritius) Pte. Ltd	4,84,44,450	15.71	3,22,96,300	-
Hyperion Investments Pte. Ltd.	10,39,49,580	33.70	7,80,39,830	51.26



ANNEXURE C

Computation of Weighted Average Price of Equity Shares acquired in the last eighteen (18) months from the date of this Certificate by the Promoters and Selling Shareholders

Nature of Transaction (Each Promoters and Selling Shareholders wise)	Nature of Consideration (Cash / other than Cash)	Date of Acquisition	No. of Equity shares	Face value of the Equity Shares (in ₹)	Acquisition per Equity Share (including securities premium) (in ₹)	Total Acquisition Cost (in ₹)	Cumulative Amount paid for the Equity Shares (in ₹)	Cumulative No. of Equity Shares
Dr. Amar Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,934	10	4,118.94	23,45,07,729.96	23,45,07,729.96	56,934
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,13,869	10	4,118.94	46,90,19,578.86	70,35,27,308.82	1,70,803
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,35,27,308.82	17,08,030
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,35,27,308.82	1,35,91,070.00
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Athiya Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	68,865	10	4,118.94	28,36,60,803.10	28,36,60,803.10	68,865
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,37,730	10	4,118.94	56,73,01,606.20	85,09,62,409.30	2,06,595
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,09,62,409.30	20,65,950
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,09,62,409.30	1,64,39,070
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Adil Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,315	10	4,118.94	23,19,58,106.10	23,19,58,106	56,315
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,12,630	10	4,118.94	46,39,16,212.20	69,58,74,318	1,68,945
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,17,63,760	1	-	-	69,58,74,318	16,89,450
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,17,63,760	1	-	-	69,58,74,318	1,34,43,210
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Anosh Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	70,506	10	4,118.94	29,04,09,983.64	29,04,09,983.64	70,506
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,41,012	10	4,118.94	58,08,19,987.28	87,12,29,950.92	2,11,518
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	87,12,29,950.92	21,15,180
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	87,12,29,950.92	1,68,30,800
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Ashvin Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	1,01,90,260	1	-	-	-	1,01,90,260
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,01,90,260	1	-	-	-	-
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Ashar Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	September 09, 2024	3,28,680	1	-	-	-	3,28,680
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	-
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Agarwal's Eye Institute - Partnership Firm								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	49,267	10	4,118.94	20,29,27,816.98	20,29,27,816.98	49,267
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	98,535	10	4,118.94	40,58,59,752.90	60,87,87,569.88	1,47,802
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,02,82,820	1	-	-	60,87,87,569.88	14,78,020
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	1,02,82,820	1	-	-	60,87,87,569.88	1,17,60,840
	Weighted average cost per Equity Share (in ₹)				51.76			
Dr. Agarwal's Eye Institute Private Limited								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	September 09, 2024	28,94,880	1	-	-	-	28,94,880
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	28,94,880	1	-	-	-	-
	Weighted average cost per Equity Share (in ₹)				51.76			
Ms. Farah Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	2,757
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	3,40,67,752.74	8,271
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	5,75,420	1	-	-	3,40,67,752.74	82,710
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	5,75,420	1	-	-	3,40,67,752.74	6,58,130
	Weighted average cost per Equity Share (in ₹)				51.76			
Ms. Urmila Agarwal								
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	2,757
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	3,40,67,752.74	8,271
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	5,75,400	1	-	-	3,40,67,752.74	82,710
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	5,75,400	1	-	-	3,40,67,752.74	6,58,110
	Weighted average cost per Equity Share (in ₹)				51.77			
Dr. Adil Agarwal Family Trust								
Gift Received	Other than cash	August 19, 2024	1	10	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than cash	August 19, 2024	1	10	-	-	-	10



Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (In ₹)							
Dr. Anosh Agarwal Family Trust							
Gift Received	Other than cash	August 20, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (In ₹)							
Dr. Ashvin Agarwal Family Trust							
Gift Received	Other than cash	August 19, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (In ₹)							
Dr. Ashar Agarwal Family Trust							
Gift Received	Other than cash	August 19, 2024	1	10	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	20	1	-	-	10
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	20	1	-	-	30
Weighted average cost per Equity Share (In ₹)							
Arvon Investments Pte. Ltd							
Rights issue	Cash	August 10, 2023	5,24,406	10	4,576.60	2,39,99,96,499.60	5,24,406
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	2,55,72,320	1	-	2,39,99,96,499.60	52,44,060
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	2,55,72,320	1	-	2,39,99,96,499.60	3,08,16,380
Weighted average cost per Equity Share (In ₹)							
Claymore Investments (Mauritius) Pte. Ltd							
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	3,22,96,300	1	-	-	3,22,96,300
Weighted average cost per Equity Share (In ₹)							
Hyperion Investments Pte. Ltd.							
Rights issue	Cash	August 10, 2023	8,74,011	10	4,576.60	4,00,00,00,000.00	8,74,011
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	6,92,98,720	1	-	4,00,00,00,000.00	87,40,110
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	6,92,98,720	1	-	4,00,00,00,000.00	7,80,39,830
Weighted average cost per Equity Share (In ₹)							
						51.26	



ANNEXURE D

Summary of Average Cost Of Acquisition of Equity Shares by the Promoters and Selling Shareholders
(since the date of first subscription to MoA till the date of this Certificate)

Name of the Promoters and Selling Shareholders	No. of Equity Shares held as of January 23, 2025	% of Pre-Offer paid-up share capital on fully diluted basis	Average Cost of Acquisition per share (In ₹)
Promoters and Promoter Group			
Dr. Amar Agarwal	1,78,24,560	5.78	117.97
Dr. Athiya Agarwal	2,15,59,680	6.99	137.63
Dr. Adil Agarwal	1,76,30,640	5.71	137.63
Dr. Anosh Agarwal	2,20,73,430	7.16	148.09
Dr. Ashvin Agarwal	1,52,85,390	4.95	0.50
Dr. Ashar Agarwal	4,93,020	0.16	-
Dr. Agarwal's Eye Institute - Partnership Firm	1,54,24,230	5.00	205.95
Dr. Agarwal's Eye Institute Private Limited	43,42,320	1.41	-
Dr. Adil Agarwal Family Trust	30	Negligible	-
Dr. Anosh Agarwal Family Trust	30	Negligible	-
Dr. Ashvin Agarwal Family Trust	30	Negligible	-
Dr. Ashar Agarwal Family Trust	30	Negligible	-
Dr. Amar Agarwal Family Trust	30	Negligible	-
Ms. Farah Agarwal	8,63,130	0.28	165.16
Ms. Urmila Agarwal	8,63,100	0.28	165.16
Selling Shareholders			
Arvon Investments Pte. Ltd	3,83,58,480	12.44	288.66
Claymore Investments (Mauritius) Pte. Ltd	4,84,44,450	15.71	125.40
Hyperion Investments Pte. Ltd.	10,39,49,580	33.70	273.70



ANNEXURE D

Computation of Average Cost Of Acquisition of Equity Shares by the Promoters and Selling Shareholders since the date of first subscription to MoA till the date of this Certificate

Nature of Transaction (Each Promoters and Selling Shareholders wise)	Nature of Consideration (Cash / other than Cash)	Date of Acquisition / Transfer	No. of Equity shares	Face value of the Equity Shares (in ₹)	Acquisition or Transfer Cost per Equity Share (including securities premium) (in ₹)	Total Acquisition / Transfer Cost (in ₹)	Cumulative Amount paid for the Equity Shares (in ₹)	Cumulative No. of Equity Shares
Dr. Amar Agarwal								
Allotment pursuant to subscription to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights Issue	Cash	January 07, 2011	2,60,000	10	10.00	26,00,000.00	27,00,000.00	2,70,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,51,620	10	-	-	27,00,000.00	4,21,620
Gift Received	Other than Cash	June 07, 2018	5,030	10	-	-	27,00,000.00	4,26,650
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,934	10	4,118.94	23,45,07,729.96	23,72,07,729.96	4,83,784
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,13,859	10	4,118.94	46,90,19,578.86	70,62,27,308.82	5,97,653
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,18,85,040	1	-	-	70,62,27,308.82	69,76,530
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,18,85,040	1	-	-	70,62,27,308.82	1,78,59,570.00
Average cost per Equity Share (in ₹)								
117.97								
Dr. Athiya Agarwal								
Allotment pursuant to subscription to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights Issue	Cash	January 07, 2011	4,00,000	10	10.00	40,00,000.00	41,00,000.00	4,10,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,19,586	10	-	-	41,00,000.00	5,23,586
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	68,865	10	4,118.94	28,36,50,803.10	28,77,50,803.10	5,92,451
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,37,730	10	4,118.94	56,73,01,606.20	85,50,52,409.30	7,30,181
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,50,52,409.30	73,01,910
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,50,52,409.30	2,16,74,930
Average cost per Equity Share (in ₹)								
137.63								
Dr. Adil Agarwal								
Allotment pursuant to subscription to the Memorandum of Association	Cash	April 19, 2010	9,500	10	10.00	95,000.00	95,000.00	9,500
Rights Issue	Cash	January 07, 2011	3,80,000	10	10.00	38,00,000.00	38,95,000.00	3,89,500
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,22,465	10	-	-	38,95,000.00	5,11,965
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,315	10	4,118.94	23,19,58,106.10	23,58,53,106.10	5,68,300
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,12,630	10	4,118.94	46,39,16,212.20	69,97,69,318	6,80,930
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,17,53,760	1	-	-	69,97,69,318	88,09,300
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,17,53,760	1	-	-	69,97,69,318	1,85,63,060
Average cost per Equity Share (in ₹)								
137.63								
Dr. Anosh Agarwal								
Allotment pursuant to subscription to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights Issue	Cash	January 07, 2011	4,00,000	10	10.00	40,00,000.00	41,00,000.00	4,10,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,17,975	10	-	-	41,00,000.00	5,27,975
Transfer - Purchase	Cash	December 29, 2017	14,230	10	2,108.22	2,99,99,970.60	3,40,99,970.60	5,42,205
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	70,506	10	4,118.94	29,04,09,883.64	32,45,09,854.24	6,12,711
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,41,012	10	4,118.94	58,08,19,967.28	90,53,29,921.52	7,53,723
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	90,53,29,921.52	75,37,230
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	90,53,29,921.52	2,22,52,850
Average cost per Equity Share (in ₹)								
148.09								
Dr. Ashwin Agarwal								
Allotment pursuant to subscription to the Memorandum of Association	Cash	April 19, 2010	9,500	10	10.00	95,000.00	95,000.00	9,500
Rights Issue	Cash	January 07, 2011	3,80,000	10	10.00	38,00,000.00	38,95,000.00	3,89,500
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,20,014	10	-	-	38,95,000.00	5,09,514
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,01,90,260	1	-	-	38,95,000.00	50,95,140
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,01,90,260	1	-	-	38,95,000.00	1,52,85,400
Average cost per Equity Share (in ₹)								
0.50								
Dr. Ashar Agarwal								
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	16,435	10	-	-	-	16,435
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	1,64,350
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	4,93,030



Average cost per Equity Share (in ₹)									
Dr. Agarwal's Eye Institute - Partnership Firm									
Allotment pursuant to scheme of amalgamation approved by NCLT order on August 31, 2018									
Other than Cash	November 17, 2018	3,66,339	10	-	-	-	-	-	3,66,339
Allotment of equity shares pursuant to conversion of series D1-CCPS									
Cash	August 28, 2024	49,287	10	4,118.94	20,29,27,816.98	20,29,27,816.98	-	-	4,15,605
Allotment of equity shares pursuant to conversion of series D2-CCPS									
Cash	August 28, 2024	98,535	10	4,118.94	40,58,59,752.90	40,58,59,752.90	-	-	5,14,141
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	1,02,82,820	1	-	-	60,87,87,569.88	60,87,87,569.88	-	51,41,410
Average cost per Equity Share (in ₹)									
205.95									
Dr. Agarwal's Eye Institute Private Limited									
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited									
Other than Cash	April 26, 2012	1,44,744	10	-	-	-	-	-	1,44,744
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	28,94,890	1	-	-	-	-	-	14,47,440
Average cost per Equity Share (in ₹)									
28,94,890									
Ms. Farah Agarwal									
Allotment pursuant to subscription to the Memorandum of Association									
Cash	April 18, 2010	500	10	10.00	5,000.00	5,000.00	-	-	500
Rights issue	January 07, 2011	20,000	10	10.00	2,00,000.00	2,00,000.00	-	-	20,500
Allotment of equity shares pursuant to conversion of series D1-CCPS									
Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	-	-	23,257
Allotment of equity shares pursuant to conversion of series D2-CCPS									
Cash	August 28, 2024	5,514	10	4,118.94	3,42,72,752.74	3,42,72,752.74	-	-	26,771
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	5,75,420	1	-	-	3,42,72,752.74	3,42,72,752.74	-	2,87,710
Average cost per Equity Share (in ₹)									
165.16									
Ms. Urmila Agarwal									
Allotment pursuant to subscription to the Memorandum of Association									
Cash	April 18, 2010	500	10	10.00	5,000.00	5,000.00	-	-	500
Rights issue	January 07, 2011	20,000	10	10.00	2,00,000.00	2,00,000.00	-	-	20,500
Allotment of equity shares pursuant to conversion of series D1-CCPS									
Cash	August 28, 2024	2,757	10	4,118.94	1,13,55,917.58	1,13,55,917.58	-	-	23,257
Allotment of equity shares pursuant to conversion of series D2-CCPS									
Cash	August 28, 2024	5,514	10	4,118.94	3,42,72,752.74	3,42,72,752.74	-	-	28,771
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	5,75,400	1	-	-	3,42,72,752.74	3,42,72,752.74	-	2,87,710
Average cost per Equity Share (in ₹)									
165.16									
Dr. Aditi Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	20	1	-	-	-	-	-	10
Average cost per Equity Share (in ₹)									
20									
Dr. Anosh Agarwal Family Trust									
Gift Received									
Other than cash	August 20, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	20	1	-	-	-	-	-	10
Average cost per Equity Share (in ₹)									
20									
Dr. Ashwin Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	20	1	-	-	-	-	-	10
Average cost per Equity Share (in ₹)									
20									
Dr. Ashar Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	20	1	-	-	-	-	-	10
Average cost per Equity Share (in ₹)									
20									
Dr. Amar Agarwal Family Trust									
Gift Received									
Other than cash	August 20, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	20	1	-	-	-	-	-	10
Average cost per Equity Share (in ₹)									
20									
Avon Investments Pte. Ltd									
Allotment of Equity Shares pursuant to conversion of Series C-CCPS									
Cash	April 26, 2022	53,024	10	3,185.67	16,89,16,966.08	16,89,16,966.08	-	-	53,024
Private placement									
Cash	May 05, 2022	5,96,420	10	3,185.67	1,89,99,97,301.40	2,06,89,14,287.48	-	-	6,49,444
Transfer - Purchase									
Cash	May 05, 2022	11,524	10	3,185.74	3,67,12,500.00	2,10,56,26,767.48	-	-	6,60,968
Transfer - Purchase									
Cash	May 05, 2022	93,242	10	3,185.66	29,70,37,500.00	2,40,26,64,267.48	-	-	7,54,210
Rights issue									
Cash	August 10, 2023	5,24,408	10	4,576.60	2,39,95,96,489.60	4,80,26,60,767.08	-	-	12,78,616
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each									
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	September 09, 2024	2,55,72,320	1	-	-	4,80,26,60,767.08	4,80,26,60,767.08	-	1,27,86,160
Average cost per Equity Share (in ₹)									
288.66									
Claymore Investments (Mauritius) Pte. Ltd									



ANNEXURE E

Summary of Weighted Average Cost Of Acquisition of Equity Shares by the Promoters and Selling Shareholders
(since the date of first subscription to MoA till the date of this Certificate)


Name of the Promoters and Selling Shareholders	No. of Equity Shares held as of January 23, 2025	% of Pre-Offer paid-up share capital on fully diluted basis	Weighted Average Cost of Acquisition per share (In ₹)
Promoters and Promoter Group			
Dr. Amar Agarwal	1,78,24,560	5.78	39.54
Dr. Athiya Agarwal	2,15,59,680	6.99	39.45
Dr. Adil Agarwal	1,76,30,640	5.71	37.70
Dr. Anosh Agarwal	2,20,73,430	7.16	40.68
Dr. Ashvin Agarwal	1,52,85,390	4.95	0.25
Dr. Ashar Agarwal	4,93,020	0.16	-
Dr. Agarwal's Eye Institute - Partnership Firm	1,54,24,230	5.00	39.47
Dr. Agarwal's Eye Institute Private Limited	43,42,320	1.41	-
Dr. Adil Agarwal Family Trust	30	Negligible	-
Dr. Anosh Agarwal Family Trust	30	Negligible	-
Dr. Ashvin Agarwal Family Trust	30	Negligible	-
Dr. Ashar Agarwal Family Trust	30	Negligible	-
Dr. Amar Agarwal Family Trust	30	Negligible	-
Ms. Farah Agarwal	8,63,130	0.28	39.71
Ms. Urmila Agarwal	8,63,100	0.28	39.71
Selling Shareholders			
Arvon Investments Pte. Ltd	3,83,58,480	12.44	125.20
Claymore Investments (Mauritius) Pte. Ltd	4,84,44,450	15.71	55.73
Hyperion Investments Pte. Ltd.	10,39,49,580	33.70	117.88



ANNEXURE E

Computation of Weighted Average Cost Of Acquisition of Equity Shares by the Promoters and Selling Shareholders since the date of first subscription to MoA till the date of this Certificate

Nature of Transaction (Each Promoters and Selling Shareholders wise)	Nature of Consideration (Cash / other than Cash)	Date of Acquisition / Transfer	No. of Equity shares	Face value of the Equity Shares (in ₹)	Acquisition or Transfer Cost per Equity Share (including securities premium) (in ₹)	Total Acquisition / Transfer Cost (in ₹)	Cumulative Amount paid for the Equity Shares (in ₹)	Cumulative No. of Equity Shares
Dr. Amar Agarwal								
Allotment pursuant to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights issue	Cash	January 07, 2011	2,60,000	10	10.00	26,00,000.00	27,00,000.00	2,70,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,51,820	10	-	-	27,00,000.00	4,21,820
Gift Received	Other than Cash	June 07, 2018	5,030	10	-	-	27,00,000.00	4,26,850
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,934	10	4,118.94	23,45,07,729.96	23,72,07,729.96	4,83,784
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,13,869	10	4,118.94	46,90,19,578.86	70,62,27,308.82	5,97,653
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,62,27,308.82	59,76,530
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,18,83,040	1	-	-	70,62,27,308.82	1,78,59,570.00
Weighted average cost per Equity Share (in ₹)								
					39.54			
Dr. Athiya Agarwal								
Allotment pursuant to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights issue	Cash	January 07, 2011	4,00,000	10	10.00	40,00,000.00	41,00,000.00	4,10,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,13,586	10	-	-	41,00,000.00	5,23,586
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	68,865	10	4,118.94	28,36,50,803.10	28,77,50,803.10	5,92,451
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,37,730	10	4,118.94	56,73,01,606.20	85,50,52,409.30	7,30,181
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,50,52,409.30	73,01,810
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,43,73,120	1	-	-	85,50,52,409.30	2,16,74,930
Weighted average cost per Equity Share (in ₹)								
					39.45			
Dr. Adil Agarwal								
Allotment pursuant to the Memorandum of Association	Cash	April 19, 2010	9,500	10	10.00	95,000.00	95,000.00	9,500
Rights issue	Cash	January 07, 2011	3,80,000	10	10.00	38,00,000.00	38,95,000.00	3,89,500
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,22,465	10	-	-	38,95,000.00	5,11,965
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	56,315	10	4,118.94	23,19,58,106.10	23,58,53,106	5,68,300
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,12,630	10	4,118.94	46,39,16,212.20	69,97,69,318	6,80,930
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,17,53,760	1	-	-	69,97,69,318	68,09,300
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,17,53,760	1	-	-	69,97,69,318	1,85,63,060
Weighted average cost per Equity Share (in ₹)								
					37.70			
Dr. Anosh Agarwal								
Allotment pursuant to the Memorandum of Association	Cash	April 19, 2010	10,000	10	10.00	1,00,000.00	1,00,000.00	10,000
Rights issue	Cash	January 07, 2011	4,00,000	10	10.00	40,00,000.00	41,00,000.00	4,10,000
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,17,975	10	-	-	41,00,000.00	5,27,975
Transfer - Purchase	Cash	December 29, 2017	14,230	10	2,108.22	2,99,99,970.60	3,40,99,970.60	5,42,205
Allotment of equity shares pursuant to conversion of series D1-CCPS	Cash	August 28, 2024	70,506	10	4,118.94	29,04,09,983.64	32,45,09,954.24	6,12,711
Allotment of equity shares pursuant to conversion of series D2-CCPS	Cash	August 28, 2024	1,41,012	10	4,118.94	58,08,19,967.28	90,53,29,921.52	7,53,723
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	90,53,29,921.52	75,37,230
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,47,15,620	1	-	-	90,53,29,921.52	2,22,52,850
Weighted average cost per Equity Share (in ₹)								
					40.68			
Dr. Ashvin Agarwal								
Allotment pursuant to the Memorandum of Association	Cash	April 19, 2010	9,500	10	10.00	95,000.00	95,000.00	9,500
Rights issue	Cash	January 07, 2011	3,80,000	10	10.00	38,00,000.00	38,95,000.00	3,89,500
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	1,20,014	10	-	-	38,95,000.00	5,09,514
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.	Other than Cash	September 09, 2024	1,01,90,280	1	-	-	38,95,000.00	50,95,140
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares	Other than Cash	September 09, 2024	1,01,90,280	1	-	-	38,95,000.00	1,52,85,400
Weighted average cost per Equity Share (in ₹)								
					0.25			
Dr. Ashar Agarwal								
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited	Other than Cash	April 26, 2012	18,435	10	-	-	-	18,435



Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Bonus issue in the ratio of 2 Equity Shares for every 1 Equity Shares	Other than Cash	September 09, 2024	3,28,680	1	-	-	-	-	1,64,350
Weighted average cost per Equity Share (in ₹)									
Dr. Agarwal's Eye Institute - Partnership Firm									
Allotment pursuant to scheme of amalgamation approved by NCI.I order on August 31, 2018.									
Other than Cash	November 17, 2018	3,86,339	10	-	-	-	-	-	3,86,339
Cash	August 28, 2024	49,267	10	4,118.94	20,29,27,816.98	-	-	-	4,15,606
Cash	August 28, 2024	98,535	10	4,118.94	40,58,59,752.90	-	-	-	5,14,141
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	1,02,82,820	1	-	-	-	-	-	51,41,410
Weighted average cost per Equity Share (in ₹)									
Dr. Agarwal's Eye Institute Private Limited									
Shares acquired pursuant to acquisition of Dr. Agarwal's Eye Hospital Limited									
Other than Cash	April 26, 2012	1,44,744	10	-	-	-	-	-	1,44,744
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	28,94,880	1	-	-	-	-	-	14,47,440
Weighted average cost per Equity Share (in ₹)									
Ms. Farah Agarwal									
Allotment pursuant to subscription to the Memorandum of Association.									
Cash	April 19, 2010	500	10	10.00	5,000.00	-	-	-	500
Cash	January 07, 2011	20,000	10	10.00	2,00,000.00	-	-	-	20,500
Cash	August 28, 2024	2,757	10	4,118.94	1,15,60,917.58	-	-	-	23,257
Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	-	-	-	28,771
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	5,75,420	1	-	-	-	-	-	2,87,710
Weighted average cost per Equity Share (in ₹)									
Ms. Urmila Agarwal									
Allotment pursuant to subscription to the Memorandum of Association.									
Cash	April 19, 2010	500	10	10.00	5,000.00	-	-	-	500
Cash	January 07, 2011	20,000	10	10.00	2,00,000.00	-	-	-	20,500
Cash	August 28, 2024	2,757	10	4,118.94	1,15,60,917.58	-	-	-	23,257
Cash	August 28, 2024	5,514	10	4,118.94	2,27,11,835.16	-	-	-	28,771
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	5,75,400	1	-	-	-	-	-	8,63,110
Weighted average cost per Equity Share (in ₹)									
Dr. Adil Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	20	1	-	-	-	-	-	30
Weighted average cost per Equity Share (in ₹)									
Dr. Anosh Agarwal Family Trust									
Gift Received									
Other than cash	August 20, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	20	1	-	-	-	-	-	30
Weighted average cost per Equity Share (in ₹)									
Dr. Ashwin Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	20	1	-	-	-	-	-	30
Weighted average cost per Equity Share (in ₹)									
Dr. Ashar Agarwal Family Trust									
Gift Received									
Other than cash	August 19, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	20	1	-	-	-	-	-	30
Weighted average cost per Equity Share (in ₹)									
Dr. Amar Agarwal Family Trust									
Gift Received									
Other than cash	August 20, 2024	1	10	-	-	-	-	-	1
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.									
Other than Cash	September 09, 2024	20	1	-	-	-	-	-	30
Weighted average cost per Equity Share (in ₹)									
Arvon Investments Pte. Ltd									
Allotment of Equity Shares pursuant to conversion of Series C-CCPS									
Cash	April 26, 2022	53,024	10	3,185.67	16,89,16,966.08	-	-	-	53,024
Cash	May 05, 2022	5,96,420	10	3,185.67	1,89,99,937,301.40	-	-	-	6,49,444
Cash	May 05, 2022	11,524	10	3,185.74	3,67,12,500.00	-	-	-	6,00,968
Cash	May 05, 2022	93,249	10	3,185.66	29,70,37,500.00	-	-	-	7,54,210
Cash	August 10, 2023	5,74,063	10	4,576.60	2,39,99,96,499.60	-	-	-	12,78,616
Weighted average cost per Equity Share (in ₹)									



Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.						
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares		Other than Cash	September 09, 2024	1	-	4,80,26,60,767.08
		Weighted average cost per Equity Share (in ₹)			125.20	3,83,58,480
Claymore Investments (Mauritius) Pte. Ltd						
Private placement:		Cash	February 13, 2019	14,77,256	10	2,46,99,72,032.00
Transfer - Purchase		Cash	February 20, 2019	1,19,617	10	2,66,99,72,032.00
Transfer - Purchase		Cash	March 25, 2019	17,942	10	2,69,99,72,032.00
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.						1,61,48,150
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares		Other than Cash	September 09, 2024	3,22,96,300	1	2,69,99,72,032.00
		Weighted average cost per Equity Share (in ₹)			55.73	4,84,44,450
Hypertion Investments Pte. Ltd.						
Private placement:		Cash	May 05, 2022	3,45,296	10	1,09,99,99,108.32
Transfer - Purchase		Cash	May 05, 2022	22,45,679	10	8,25,40,06,718.32
Rights issue		Cash	August 10, 2023	8,74,011	10	12,25,40,06,718.32
Pursuant to the special resolution passed by shareholders dated September 05, 2024, Company sub-divided the face value of its Equity Shares from ₹ 10 each to ₹ 1 each.						3,46,49,860
Bonus issue in the ratio of 2 Equity Share for every 1 Equity Shares		Other than Cash	September 09, 2024	6,92,99,720	1	12,25,40,06,718.32
		Weighted average cost per Equity Share (in ₹)			117.88	10,39,49,580



ANNEXURE G

Weighted average cost of acquisition per Equity Share for primary issuance (excluding shares issued under ESOP / ESOS and bonus shares) during last eighteen (18) months from the date of this Certificate and where such issuance was equal to or more than 5% of fully diluted paid up share capital of the Company before such issuance.

0	Date of Issuance (Primary)	Name of Allotees	Pre Split and Bonus Issue				Post Split and Bonus Issue				
			% of paid up capital (on a fully diluted basis prior to allotment)	Face value of the Equity Shares (in ₹)	No. of Equity Shares	Acquisition per Equity Share (including securities premium) (in ₹)	Total Acquisition Cost (in ₹)	Face value of the Equity Shares (in ₹)	No. of Equity Shares	Acquisition per Equity Share (including securities premium) (in ₹)	Total Acquisition Cost (in ₹)
1	August 10, 2023	Arvon Investments Pte. Ltd - 5,24,406 Hyperion Investments Pte. Ltd - 8,74,011	0.00%	10	13,98,417	4,576.60	6,39,99,96,496.60	1	4,19,52,510	152.55	6,38,99,96,499.60
2 nd	August 28, 2024	Amer Agarwal - 1,70,803, Athiya Agarwal - 2,06,595, Aditi Agarwal - 1,68,945, Anosh Agarwal - 2,11,516, Farah Agarwal - 8,271, Urmilia Agarwal - 8,271 and Anosh Agarwal (on behalf of Dr. Agarwal's Eye Institute (Partnership Firm)) - 1,47,802.	9.56%	10	9,22,205	4,118.84	3,79,85,07,062.70	1	2,76,66,150	137.30	3,79,85,07,062.70
		Total			23,20,622		10,19,85,03,562.30		6,96,18,660		10,19,85,03,562.30
							4,394.73				146.49

* Note: Issuance pursuant to CCPS Conversion of D1 and D2 Series occurred over a span of rolling 30 days are combined together for the calculation of more than 5% of fully diluted paid up share capital of the Company.



ANNEXURE H

Weighted average cost of acquisition per Equity Share for secondary issuance during last eighteen (18) months from the date of this Certificate (excluding gifts) and where such issuance was equal to or more than 5% of fully diluted paid up share capital of the Company before such issuance.

Date of Issuance (Secondary Sale / Acquisition)	Name of Transferor and Transferee	No. of Equity Shares Sold / Acquired	% of paid up capital (on a fully diluted basis prior to sale / acquisition)	Price per Equity Shares Sold / Acquired
Nil				
Weighted average cost of acquisition (in ₹)				Nil



ANNEXURE I

WEIGHTED AVERAGE COST OF ACQUISITION (WACA) BASED ON PRIMARY/ SECONDARY TRANSACTION(S) AS DISCLOSED IN ANNEXURE G AND H

Past Transactions	WACA (in ₹)	IPO Floor Price (in ₹)	IPO Cap Price (in ₹)
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity/ convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme, and issuance of bonus shares, during the 18 months preceding the date of this Red Herring Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transactions/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	146.49	[·] times *	[·] times *
Weighted average cost of acquisition for last 18 months for secondary sale/acquisition of shares equity/convertible securities), where promoter/ promoter group entities or Selling Shareholders or shareholder(s) having the right to nominate director(s) in the Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of this Red Herring Prospectus, where either acquisition or sale is equal to or more than five per cent of the fully diluted paid-up share capital of the Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	Nil	[·] times *	[·] times *

* To be updated upon finalization of the price band

